TRDANasdaqPharmaceutical PreparationsUS GAAP · USD

Entrada Therapeutics, Inc.

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines designed to reach intracellular targets that have historically been difficult to access. Its pipeline is focused on neuromuscular and inherited retinal diseases, with lead programs in Duchenne muscular dystrophy and a partnered myotonic dystrophy program with Vertex.

Kysy yhtiöstä
Liikevaihto25,4milj. USD
−87,9 %v/v
Liikevoitto (EBIT)−158milj. USD
−435,9 %v/v
EBIT-marginaali−621,1%
−643,4 %-yks.v/v
Nettotulos−144milj. USD
−319,0 %v/v
Vapaa kassavirta−130milj. USD
−189,7 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−200−1000100200300milj. USD2020: EBIT −27 milj. USD20202021: EBIT −51 milj. USD20212022: EBIT −97 milj. USD20222023: 129 milj. USD2023: EBIT −3,2 milj. USD20232024: 211 milj. USD2024: EBIT 47 milj. USD20242025: 25 milj. USD2025: EBIT −158 milj. USD202525−158
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Entrada Therapeutics, Inc.

Liiketoiminta

Osuus liikevaihdosta
Clinical-stage DMD programs0 %

Lead exon-skipping and genetic medicine candidates for Duchenne muscular dystrophy.

Partnered neuromuscular program100 %

VX-670 collaboration with Vertex for myotonic dystrophy type 1.

Platform technology0 %

Endosomal Escape Vehicle platform used to deliver therapeutics into cells.

Preclinical discovery pipeline0 %

Earlier-stage programs in neuromuscular and inherited retinal diseases.

Asiakkaat

Entrada does not yet sell approved products; its current economic counterparties are collaboration partners, regulators, clinical investigators, and trial sites rather than end-market patients. If approved, its therapies would be prescribed by physicians and reimbursed by third-party payors for rare disease patients, especially in neuromuscular and inherited retinal disease populations.

Strategic collaboration partner

Vertex funds and co-develops VX-670, providing non-product revenue and development support.

Clinical trial patients

Patients with DMD and DM1 who enroll in studies and generate clinical data needed for approval.

Physicians and specialty centers

Neuromuscular specialists and treatment centers that would diagnose, prescribe, and monitor therapy.

Third-party payors

Insurers and public payors that would determine access and reimbursement for any approved medicines.

Strategia

Entrada's strategy is to validate its EEV platform through clinical readouts in DMD and through the Vertex-partnered VX-670 program, then expand into additional indications. Near term, it is focused on advancing multiple clinical trials, securing regulatory filings, and using early data from one program to inform the rest of the pipeline.

Clinical advancement of lead DMD programsLyhyt aikaväli

Human data is the main value driver for a clinical-stage biotech and de-risks the platform.

Platform validation through shared EEV biologyKeskipitkä aikaväli

Success in one candidate can support the broader pipeline and improve partnering leverage.

Partnership execution with VertexLyhyt aikaväli

Collaboration revenue and external validation reduce funding pressure and broaden development reach.

Maantiede

Entrada is headquartered in the United States, but its clinical development footprint spans the U.S., the U.K., and the European Union. The company specifically highlighted DMD programs in the U.K., EU, and U.S., and it expects an EU filing for ENTR-601-50, making Europe an important regulatory and trial geography.

Riskit

Entrada is exposed to the binary risk profile of clinical-stage drug development: programs can fail on safety, efficacy, manufacturing, or regulatory grounds. It also depends on continued financing and on the success of a small number of lead assets, so delays in clinical milestones or partner execution could materially affect the business.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Regulatory and approval delays2Financing risk3Manufacturing scale-up and supply risk4Partner concentration5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea

    The company has no approved products and relies on a small number of programs to prove efficacy and safety.

    KohdistuuENTR-601-44ENTR-601-45ENTR-601-50ENTR-601-51VX-670
  2. Regulatory and approval delaysVaikutus: KorkeaTodennäköisyys: Korkea

    Rare-disease programs require multiple agency interactions and can be slowed by additional data requests.

    KohdistuuFDAEMAEU filingFuture marketing approvals
  3. Financing riskVaikutus: KorkeaTodennäköisyys: Korkea

    The company expects operating losses and negative cash flow until product sales, if ever, begin.

    KohdistuuNeed for equityDebtOr collaboration funding
  4. Manufacturing scale-up and supply riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    EEV-based therapeutics have not been manufactured at commercial scale and may be difficult to scale reliably.

    Kohdistuu: Clinical and future commercial supply

  5. Partner concentrationVaikutus: KeskitasoTodennäköisyys: Matala

    A substantial portion of revenue to date has come from the Vertex agreement.

    Kohdistuu: Collaboration revenue and development support

Kysy Clarifolta: Entrada Therapeutics, Inc.

Kirjanpito

Harkinnanvaraiset erät
ASC 606 collaboration revenue

Revenue depends on performance obligations and milestone timing under the Vertex agreement.

Vaikutus: Can shift revenue between periods without changing underlying cash generation

Research and development expense estimation

Clinical trial, manufacturing, and preclinical costs require accrual estimates and can be volatile.

Vaikutus: Affects operating loss and comparability across quarters

Stock-based compensation

A large portion of employee compensation is equity-based in a development-stage biotech.

Vaikutus: Impacts operating expenses and non-cash dilution analysis

Tax capitalization of R&D under Section 174

U.S. tax rules require capitalization and amortization of certain R&D costs.

Vaikutus: Affects tax expense and deferred tax timing

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Sarepta Therapeutics, Inc.

SRPT · Pharmaceutical Preparations

Dyne Therapeutics, Inc.

DYN · Pharmaceutical Preparations

Solid Biosciences Inc.

SLDB · Biological Products, (No Diagnostic Substances)

Capricor Therapeutics, Inc

CAPR · Pharmaceutical Preparations

Intensity Therapeutics, Inc

INTS · Biological Products, (No Diagnostic Substances)

Entera Bio Ltd.

ENTX · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026